Premium
FDA issues guidance on endpoints for OUD medications
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32865
Subject(s) - buprenorphine , food and drug administration , opioid use disorder , medicine , drug , opioid , pharmacology , receptor
Last week, the Food and Drug Administration (FDA) issued guidance to help pharmaceutical companies develop drugs to treat opioid use disorder (OUD), defining the endpoints that are acceptable. This guidance, which is final, builds on the draft guidance as well as another guidance about depot buprenorphine products issued last year.